STUDY OF ACID REFLUX ASTHMA (SARA)

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 本研究旨在确定酸反流（GERD）是否会导致哮喘，以及质子泵抑制剂（PPI）治疗是否会减少哮喘急性发作。 这将是一项多中心、随机、双盲、平行组临床试验，并设安慰剂对照。 在全国招募的400名患者中，预计有22名将在这里进行研究。主要结局指标是治疗期间哮喘急性发作率。 阳性终点包括与安慰剂治疗组相比，哮喘加重率较低，哮喘症状较少，生活质量较好，肺功能较好，医疗保健使用较少，气道反应性改善。 次要结局包括与峰值流量相关的可测量肺功能。 PPI是埃索美拉唑（Nexium）。 这对有症状的哮喘患者可能有很大的好处，他们可以从简单的医疗干预（质子泵抑制剂）中获益。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study is designed to determine whether acid reflux (GERD) contributes to asthma and whether treatment with a proton-pump inhibitor (PPI) will reduce asthma exacerbations. This will be conducted as a multicenter, randomized, double-masked, parallel-group clinical trial, with a placebo control. Of 400 patients to be recruited nationally, 22 are expected to be studied here. The primary outcome measure is asthma exacerbation rate during treatment. Positive endpoints would include lower rate of asthma exacerbations, fewer asthma symptoms, better quality of life, better lung function, less health care use, and improved airway reactivity compared to those treated with a placebo. Secondary outcomes include measurable lung functions related to peak flow. The PPI is esomeprazole (Nexium). This is potentially of great benefit to symptomatic asthmatics who would benefit from a simple medical intervention (proton pump inhibitor).